摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-cyclohexyloxy-pyridazine | 36988-28-0

中文名称
——
中文别名
——
英文名称
3-cyclohexyloxy-pyridazine
英文别名
3-Cyclohexyloxypyridazine
3-cyclohexyloxy-pyridazine化学式
CAS
36988-28-0
化学式
C10H14N2O
mdl
——
分子量
178.234
InChiKey
QHFXKRMMBQGBDA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES DE PYRIDAZINE ET LEURS UTILISATIONS
    申请人:GENENTECH INC
    公开号:WO2016138114A1
    公开(公告)日:2016-09-01
    The present invention relates to compounds of formula (I): (I) and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
    本发明涉及式(I)的化合物及其盐,其中:R1-R4具有规范中定义的任何值,以及其组合物和用途。这些化合物可用作BRG1、BRM和/或PB1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物,以及在治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病中使用这些化合物和盐的方法。
  • Therapeutic compounds and uses thereof
    申请人:GENENTECH, INC.
    公开号:US10308614B2
    公开(公告)日:2019-06-04
    The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
    本发明涉及式(I)化合物: 及其盐类,其中R1-R4具有说明书中定义的任何值,以及其组合物和用途。这些化合物可用作 BRG1、BRM 和/或 PB1 的抑制剂。还包括包含式(I)化合物或其药学上可接受的盐的药物组合物,以及使用此类化合物和盐治疗各种BRG1介导的疾病、BRM介导的疾病和/或PB1介导的疾病的方法。
  • THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF
    申请人:Genentech, Inc.
    公开号:EP3262036A1
    公开(公告)日:2018-01-03
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    申请人:GENENTECH, INC.
    公开号:US20180086720A1
    公开(公告)日:2018-03-29
    The present invention relates to compounds of formula (I): and salts thereof, wherein: R 1 -R 4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
查看更多